CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges

Overview

Journal Blood Lymphat Cancer

Publisher Dove Medical Press

Specialty Hematology

Date 2022 Sep 5

PMID 36060553

Authors

Matthew J Rendo

Jacinth J Joseph

Liem Minh Phan

Christin B DeStefano

Affiliations

Soon will be listed here.

Abstract

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of recently developed and investigational CAR T-cell therapies for MM, highlighting current evidence and challenges.

Citing Articles

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.

Navab R, Futela P, Kumari V, Valecha J, Gupta R, Jain R Iran J Med Sci. 2025; 50(1):1-10.

PMID: 39957814 PMC: 11829063. DOI: 10.30476/ijms.2024.101739.3446.

The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies.

Besliu C, Tanase A, Rotaru I, Espinoza J, Vidal L, Poelman M Cancers (Basel). 2025; 17(3).

PMID: 39941892 PMC: 11817212. DOI: 10.3390/cancers17030525.

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach.

Rujirachaivej P, Siriboonpiputtana T, Choomee K, Supimon K, Sangsuwannukul T, Songprakhon P J Transl Med. 2025; 23(1):54.

PMID: 39806405 PMC: 11727291. DOI: 10.1186/s12967-024-05923-z.

Complement C3d enables cell-mediated immunity capable of distinguishing spontaneously transformed from nontransformed cells.

Platt J, Zhao C, Chicca J, Pianko M, Han J, The S Proc Natl Acad Sci U S A. 2024; 121(52):e2405824121.

PMID: 39693340 PMC: 11670236. DOI: 10.1073/pnas.2405824121.

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service.

Popat R, Basu S, Henshaw S, Karunanithi K, Ramasamy K, Singh I EJHaem. 2024; 5(6):1133-1143.

PMID: 39691253 PMC: 11647736. DOI: 10.1002/jha2.1038.

References

Attal M, Harousseau J, Stoppa A, Sotto J, Fuzibet J, Rossi J . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996; 335(2):91-7. DOI: 10.1056/NEJM199607113350204. View

Costa L, Hari P, Berdeja J, De Stefano V, Gay F, Hooper B . Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2022; 38(10):1759-1767. DOI: 10.1080/03007995.2022.2100651. View

Raskov H, Orhan A, Christensen J, Gogenur I . Cytotoxic CD8 T cells in cancer and cancer immunotherapy. Br J Cancer. 2020; 124(2):359-367. PMC: 7853123. DOI: 10.1038/s41416-020-01048-4. View

Smith E, Harrington K, Staehr M, Masakayan R, Jones J, Long T . GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019; 11(485). PMC: 7508042. DOI: 10.1126/scitranslmed.aau7746. View

Chakraborty R, Siddiqi R, Willson G, Gupta S, Asghar N, Husnain M . Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials. Cancer. 2022; 128(12):2288-2297. DOI: 10.1002/cncr.34211. View

Parrondo R, Sam K, Rasheed A, Alegria V, Sher T, Roy V . Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis. Blood Cancer J. 2022; 12(4):66. PMC: 9019050. DOI: 10.1038/s41408-022-00662-0. View

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

Sanchez E, Li M, Kitto A, Li J, Wang C, Kirk D . Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012; 158(6):727-38. DOI: 10.1111/j.1365-2141.2012.09241.x. View

Karschnia P, Jordan J, Forst D, Arrillaga-Romany I, Batchelor T, Baehring J . Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019; 133(20):2212-2221. DOI: 10.1182/blood-2018-12-893396. View

10.

Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W . Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020; 13(1):164. PMC: 7713173. DOI: 10.1186/s13045-020-01001-1. View

11.

Giri S, Bal S, Godby K, Ravi G, Clark D, Ubersax C . Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma. Am J Hematol. 2022; 97(4):E153-E155. DOI: 10.1002/ajh.26472. View

12.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

13.

Rubin D, Danish H, Ali A, Li K, LaRose S, Monk A . Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019; 142(5):1334-1348. DOI: 10.1093/brain/awz053. View

14.

Ozer H, Han T, HENDERSON E, Nussbaum A, Sheedy D . Immunoregulatory T cell function in multiple myeloma. J Clin Invest. 1981; 67(3):779-89. PMC: 370629. DOI: 10.1172/JCI110095. View

15.

Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E . T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016; 9(1):116. PMC: 5093947. DOI: 10.1186/s13045-016-0345-3. View

16.

Cavo M, Gay F, Beksac M, Pantani L, Petrucci M, Dimopoulos M . Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95):.... Lancet Haematol. 2020; 7(6):e456-e468. DOI: 10.1016/S2352-3026(20)30099-5. View

17.

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

18.

Teoh P, Chng W . CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021; 11(4):84. PMC: 8085238. DOI: 10.1038/s41408-021-00469-5. View

19.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

20.

Pont M, Hill T, Cole G, Abbott J, Kelliher J, Salter A . γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134(19):1585-1597. PMC: 6871311. DOI: 10.1182/blood.2019000050. View